| The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium The Lancet 379 (9822), 1214-1224, 2012 | 1137 | 2012 |
| Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data MV Holmes, CE Dale, L Zuccolo, RJ Silverwood, Y Guo, Z Ye, ... Bmj 349, g4164, 2014 | 872 | 2014 |
| Mendelian randomization of blood lipids for coronary heart disease MV Holmes, FW Asselbergs, TM Palmer, F Drenos, MB Lanktree, ... European heart journal 36 (9), 539-550, 2015 | 821 | 2015 |
| HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials The Lancet, 2014 | 788* | 2014 |
| Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure S Shah, A Henry, C Roselli, H Lin, G Sveinbjörnsson, G Fatemifar, ... Nature communications 11 (1), 163, 2020 | 688 | 2020 |
| PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study AF Schmidt, DI Swerdlow, MV Holmes, RS Patel, Z Fairhurst-Hunter, ... The lancet Diabetes & endocrinology 5 (2), 97-105, 2017 | 413 | 2017 |
| Selecting instruments for Mendelian randomization in the wake of genome-wide association studies DI Swerdlow, KB Kuchenbaecker, S Shah, R Sofat, MV Holmes, J White, ... International journal of epidemiology 45 (5), 1600-1616, 2016 | 352 | 2016 |
| Association of lipid fractions with risks for coronary artery disease and diabetes J White, DI Swerdlow, D Preiss, Z Fairhurst-Hunter, BJ Keating, ... JAMA cardiology 1 (6), 692-699, 2016 | 320 | 2016 |
| Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci FW Asselbergs, Y Guo, EPA Van Iperen, S Sivapalaratnam, V Tragante, ... The American Journal of Human Genetics 91 (5), 823-838, 2012 | 302 | 2012 |
| Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis MV Holmes, LA Lange, T Palmer, MB Lanktree, KE North, B Almoguera, ... The American Journal of Human Genetics 94 (2), 198-208, 2014 | 265 | 2014 |
| Single ascending dose study of a short interfering RNA targeting lipoprotein (a) production in individuals with elevated plasma lipoprotein (a) levels SE Nissen, K Wolski, C Balog, DI Swerdlow, AC Scrimgeour, C Rambaran, ... Jama 327 (17), 1679-1687, 2022 | 225 | 2022 |
| Interleukin-6 receptor pathways in abdominal aortic aneurysm SC Harrison, AJP Smith, GT Jones, DI Swerdlow, R Rampuri, MJ Bown, ... European heart journal 34 (48), 3707-3716, 2013 | 201 | 2013 |
| Mendelian randomization for studying the effects of perturbing drug targets D Gill, MK Georgakis, VM Walker, AF Schmidt, A Gkatzionis, DF Freitag, ... Wellcome open research 6, 2021 | 195 | 2021 |
| Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis J White, R Sofat, G Hemani, T Shah, J Engmann, C Dale, S Shah, ... The lancet Diabetes & endocrinology 4 (4), 327-336, 2016 | 151 | 2016 |
| Secretory Phospholipase A2-IIA and Cardiovascular Disease: A Mendelian Randomization Study MV Holmes, T Simon, HJ Exeter, L Folkersen, FW Asselbergs, ... Journal of the American College of Cardiology 62 (21), 1966-1976, 2013 | 133 | 2013 |
| Genetic association of lipids and lipid drug targets with abdominal aortic aneurysm: a meta-analysis SC Harrison, MV Holmes, S Burgess, FW Asselbergs, GT Jones, AF Baas, ... JAMA cardiology 3 (1), 26-33, 2018 | 118 | 2018 |
| Gene-centric analysis identifies variants associated with interleukin-6 levels and shared pathways with other inflammation markers T Shah, D Zabaneh, T Gaunt, DI Swerdlow, S Shah, PJ Talmud, IN Day, ... Circulation: Cardiovascular Genetics 6 (2), 163-170, 2013 | 68 | 2013 |
| Causal relevance of blood lipid fractions in the development of carotid atherosclerosis: Mendelian randomization analysis S Shah, JP Casas, F Drenos, J Whittaker, J Deanfield, DI Swerdlow, ... Circulation: Cardiovascular Genetics 6 (1), 63-72, 2013 | 56 | 2013 |
| Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease DA Rider, M Eisermann, K Löffler, M Aleku, DI Swerdlow, S Dames, ... Atherosclerosis 349, 240-247, 2022 | 53 | 2022 |
| Treatment and prevention of lipoprotein (a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics DI Swerdlow, DA Rider, A Yavari, M Wikström Lindholm, GV Campion, ... Cardiovascular Research 118 (5), 1218-1231, 2022 | 53 | 2022 |